These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 9724480

  • 21. Transjugular intrahepatic portosystemic shunt following liver transplantation: can outcomes be predicted?
    El Atrache M, Abouljoud M, Sharma S, Abbass AA, Yoshida A, Kim D, Kazimi M, Moonka D, Brown K.
    Clin Transplant; 2012; 26(4):657-61. PubMed ID: 22309034
    [Abstract] [Full Text] [Related]

  • 22. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.
    Siramolpiwat S.
    World J Gastroenterol; 2014 Dec 07; 20(45):16996-7010. PubMed ID: 25493012
    [Abstract] [Full Text] [Related]

  • 23. [Percutaneous intrahepatic portosystemic shunting as a treatment for refractory hepatic hydrothorax].
    Núñez O, García A, Rincón D, Alonso S, Echenagusía A, Bañares R.
    Gastroenterol Hepatol; 2002 Mar 07; 25(3):143-7. PubMed ID: 11864535
    [Abstract] [Full Text] [Related]

  • 24. TIPS for management of portal-hypertension-related complications in patients with cirrhosis.
    Allaire M, Walter A, Sutter O, Nahon P, Ganne-Carrié N, Amathieu R, Nault JC.
    Clin Res Hepatol Gastroenterol; 2020 Jun 07; 44(3):249-263. PubMed ID: 31662286
    [Abstract] [Full Text] [Related]

  • 25. Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax.
    Strauss RM, Martin LG, Kaufman SL, Boyer TD.
    Am J Gastroenterol; 1994 Sep 07; 89(9):1520-2. PubMed ID: 8079930
    [Abstract] [Full Text] [Related]

  • 26. TIPS for management of refractory ascites: response and survival are both unpredictable.
    Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A.
    Dig Dis Sci; 2003 Mar 07; 48(3):542-50. PubMed ID: 12757168
    [Abstract] [Full Text] [Related]

  • 27. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery.
    Kim JJ, Dasika NL, Yu E, Fontana RJ.
    J Clin Gastroenterol; 2009 Jul 07; 43(6):574-9. PubMed ID: 19169145
    [Abstract] [Full Text] [Related]

  • 28. Refractory hepatic hydrothorax treated with transjugular intrahepatic portosystemic shunt.
    Degawa M, Hamasaki K, Yano K, Nakao K, Kato Y, Sakamoto I, Nakata K, Eguchi K.
    J Gastroenterol; 1999 Feb 07; 34(1):128-31. PubMed ID: 10204623
    [Abstract] [Full Text] [Related]

  • 29. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature.
    Badillo R, Rockey DC.
    Medicine (Baltimore); 2014 May 07; 93(3):135-142. PubMed ID: 24797168
    [Abstract] [Full Text] [Related]

  • 30. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D, Sponza M, Falleti E, Fabris C, Vit A, Angeli P, Piano S, Cussigh A, Cmet S, Toniutto P.
    Eur J Gastroenterol Hepatol; 2019 May 07; 31(5):626-632. PubMed ID: 30550458
    [Abstract] [Full Text] [Related]

  • 31. Transjugular intrahepatic portosystemic shunt placement before abdominal intervention in cirrhotic patients with portal hypertension: lessons from a pilot study.
    Fares N, Robic MA, Péron JM, Muscari F, Otal P, Suc B, Vinel JP, Bureau C.
    Eur J Gastroenterol Hepatol; 2018 Jan 07; 30(1):21-26. PubMed ID: 29049129
    [Abstract] [Full Text] [Related]

  • 32. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement.
    Borentain P, Soussan J, Resseguier N, Botta-Fridlund D, Dufour JC, Gérolami R, Vidal V.
    Diagn Interv Imaging; 2016 Jun 07; 97(6):643-50. PubMed ID: 26947721
    [Abstract] [Full Text] [Related]

  • 33. Transjugular intrahepatic portosystemic shunts: experience in the oncology setting.
    Wallace MJ, Madoff DC, Ahrar K, Warneke CL.
    Cancer; 2004 Jul 15; 101(2):337-45. PubMed ID: 15241832
    [Abstract] [Full Text] [Related]

  • 34. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
    Will V, Rodrigues SG, Stirnimann G, Gottardi A, Bosch J, Berzigotti A.
    United European Gastroenterol J; 2020 Oct 15; 8(8):961-969. PubMed ID: 32588789
    [Abstract] [Full Text] [Related]

  • 35. [TIPS - Transjugular intrahepatic portosystemic shunt. A review].
    Carreiro G, da Luz Moreira A, Murad FF, Azevedo F, Coelho HS.
    Arq Gastroenterol; 2001 Oct 15; 38(1):69-80. PubMed ID: 11586999
    [Abstract] [Full Text] [Related]

  • 36. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage.
    Sahagun G, Benner KG, Saxon R, Barton RE, Rabkin J, Keller FS, Rosch J.
    Am J Gastroenterol; 1997 Sep 15; 92(9):1444-52. PubMed ID: 9317060
    [Abstract] [Full Text] [Related]

  • 37. Refractory Hepatic Hydrothorax in the Absence of Ascites as a First Sign of Cirrhosis.
    Aloreidi K, Gedela M, Wabwire G, Mothapothula UM, Jha L.
    S D Med; 2018 Apr 15; 71(4):168-170. PubMed ID: 29996034
    [Abstract] [Full Text] [Related]

  • 38. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML, Asmacher S, Lehmann J, Jansen C, Görtzen J, Klein S, Meyer C, Strunk HM, Fimmers R, Tacke F, Strassburg CP, Trautwein C, Sauerbruch T, Wasmuth HE, Trebicka J.
    J Hepatol; 2015 Feb 15; 62(2):332-9. PubMed ID: 25457205
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.